Neuroendocrine Tumors-Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington.
² Neuroendocrine and Gynecologic Cancer Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
³ Medical Oncology and Clinical Endocrinology, Center for Cancer Research Rare Tumor Clinic, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Aman Chauhan et al. JAMA Oncol. 2020.

. 2020 Jan 1;6(1):21-22.

doi: 10.1001/jamaoncol.2019.4568.

¹ Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington.
² Neuroendocrine and Gynecologic Cancer Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
³ Medical Oncology and Clinical Endocrinology, Center for Cancer Research Rare Tumor Clinic, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Erratum in

Error in Figure.
[No authors listed] [No authors listed] JAMA Oncol. 2020 Jan 1;6(1):162. doi: 10.1001/jamaoncol.2019.6336. JAMA Oncol. 2020. PMID: 31917390 Free PMC article. No abstract available.

No abstract available

Competing interests

AC: Research grant from BMS, Clovis. EK and JDR: No competing interests declared.

1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. - PMC - PubMed
1. Chauhan A, Yu Q, Ray N, et al. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018;9(27):19245–19254. - PMC - PubMed
1. Hallet J, Law CHL, Cheung M, et al. Patterns and drivers of costs for neuroendocrine tumor care: A comparative population-based analysis. Ann Surg Oncol. 2017;24(11):3312–3323. - PubMed